Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Medtronic
Mallinckrodt
Dow
McKinsey

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Solabegron

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Solabegron: Sponsors, patents, clinical trial progress

Solabegron is an investigational drug.

There have been 8 clinical trials for Solabegron. The most recent clinical trial was a Phase 2 trial, which was initiated on July 9th 2018.

The most common disease conditions in clinical trials are Urinary Bladder, Overactive, Irritable Bowel Syndrome, and Syndrome. The leading clinical trial sponsors are GlaxoSmithKline, Velicept Therapeutics, Inc., and [disabled in preview].

Recent Clinical Trials for Solabegron
TitleSponsorPhase
A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001)Velicept Therapeutics, Inc.Phase 2
Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult WomenVelicept Therapeutics, Inc.Phase 2
Evaluate the Safety, Tolerability and PK of Different Formulations of Orally Administered Solabegron in Healthy Male SubjectsVelicept Therapeutics, Inc.Phase 1

See all Solabegron clinical trials

Clinical Trial Summary for Solabegron

Top disease conditions for Solabegron
Top clinical trial sponsors for Solabegron

See all Solabegron clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Merck
Dow
AstraZeneca
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.